Savara (SVRA) EBT Margin (2013 - 2020)

Savara's (SVRA) quarterly EBT Margin came in at 248259200.0% in Q4 2020, down 5648171.88% on a QoQ basis from 4395.31% in Q3 2020.

Savara (SVRA) EBT Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has 5 years of EBT Margin data on file, last reported at 248259200.0% in Q4 2020.

On a quarterly basis, EBT Margin changed N/A year-over-year to 248259200.0% in Q4 2020; TTM through Mar 2022 was 4041700.0%, a N/A change from a year earlier, with the FY2020 full-year figure at 980290.66%, changed N/A from the prior year.
EBT Margin for Q4 2020 stood at 248259200.0%, down from 4395.31% in the prior quarter.
Over the last five years, EBT Margin for SVRA reached as high as 12738.3% in Q2 2017 and fell as low as 248259200.0% in Q4 2020.
Historically, EBT Margin has averaged 41377378.62% across 3 years, with a median of 4969.46% in 2017.
On a YoY basis, EBT Margin climbed as much as 2182037 bps in 2016 and fell as far as 2182037 bps in 2016.
Year by year, EBT Margin stood at 700.0% in 2016, then jumped by 1920 bps to 12738.3% in 2017, then plunged by 1949020 bps to 248259200.0% in 2020.
Per Business Quant data, the three most recent EBT Margin figures were 248259200.0% in Q4 2020, 4395.31% in Q3 2020, and 12738.3% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Savara	1.24 Bn	1.24 Bn	-	-

Download Data